Elaine Chen
Elaine Chen reports on the biopharma industry for STAT, connecting the science of new medicines with the business, regulatory, and political forces that shape them. Her coverage is distinguished by a sustained focus on obesity and cardiometabolic drugs, and on how payment models, FDA decisions, and investor expectations determine which therapies reach patients. She moves fluently between clinical questions — such as the use of GLP-1 therapies in conditions like peripheral artery disease — and the competitive dynamics among drug makers developing these treatments. Her work spans breaking industry news, deeper analytical features, a daily biotech newsletter, and a weekly podcast, giving her a broad lens on how biotech developments land across the ecosystem.
Obesity and cardiometabolic therapies
Obesity drugs are a central thread in Chen’s reporting, and she returns to them as a way to examine both clinical progress and industry strategy. She covers the boom in new obesity treatments, paying close attention to GLP-1 drugs and other metabolic therapies, and how companies position these medicines in a rapidly intensifying market. Her work has dissected how major manufacturers of obesity drugs lost ground in the market, exploring how internal caution, missed bets, and shifting expectations allowed rivals to gain advantage. She also reports on unusual access decisions and patient stories around obesity medicines, such as cases where drug makers grant extraordinary access to older patients, to illustrate how clinical criteria and commercial considerations intersect.
Chen’s coverage of GLP-1 drugs extends beyond weight loss to cardiometabolic and vascular outcomes, including their use in conditions like peripheral artery disease. That focus reflects her background covering heart and metabolic conditions, such as diabetes and obesity, and her ability to track how these therapeutic areas are evolving as obesity drugs move into broader cardiovascular indications. Across these stories, she combines trial results, regulatory updates, company commentary, and investor reaction to show how evidence is translated into commercial strategy and clinical practice.
Biopharma business, regulation, and investment
Chen consistently examines how payment models, FDA changes, and policy debates reshape the biopharma landscape. Her stories explore new drug payment approaches, looking at how insurers, pharmacy benefit managers, and manufacturers structure reimbursement for costly therapies, and how those decisions affect patient access and company revenues. She reports on the ways companies are affected by FDA decisions, tracking how regulatory shifts alter pipelines, delay launches, or prompt strategic pivots.
On the business side, Chen covers national biotech and pharma stories, including licensing deals, partnerships, and portfolio changes, often explaining why particular transactions matter for specific therapeutic areas. Her reporting on ARCH-launched Neumora stopping a depression program, for example, uses that decision to illustrate how neuroscience programs are reprioritized in response to data, funding pressures, and competitive landscapes. She also contributes to coverage of biotech venture firm rankings and longevity-focused investment bets, linking capital flows to emerging scientific themes and geopolitical concerns, including efforts to guard domestic biotech from strategic risks associated with China.
Investor sentiment is a recurring element in her work. In coverage highlighted by industry leaders, she has shown how companies’ attempts to manage expectations around obesity and other high-profile drugs can still leave investors disappointed, and what that disconnect reveals about the market’s appetite for risk and growth. These stories position Chen as a reporter who explains not only what deals and data releases occur, but how they are interpreted by investors and regulators.
Psychedelics and emerging modalities
Beyond obesity and traditional small molecules, Chen reports on emerging modalities such as psychedelic therapies and peptide-based drugs. In her coverage of psychedelic biotechs, she has detailed how companies use promotional videos and influencer marketing to build awareness, and how those tactics come under scrutiny from regulators and critics concerned about responsible communication of experimental therapies. She treats these stories as case studies in the evolving boundaries between scientific messaging, consumer-style marketing, and securities regulation.
Her reporting on peptides moving into the mainstream similarly tracks the shift from niche scientific interest to broader commercial adoption. She looks at how new peptide therapies are framed to clinicians, patients, and investors, and how they fit into the wider landscape of obesity and metabolic drugs. Across these areas, Chen focuses on the intersection of innovation and oversight, showing how novel modalities test existing regulatory frameworks and ethical norms.
The Readout newsletter and biotech podcast
Chen extends her reporting beyond traditional articles by co-authoring The Readout, STAT’s newsletter on the business, science, and politics of biotech. Through this format, she provides regular, concise analysis of industry developments, highlighting notable trial readouts, regulatory actions, financings, and corporate shifts that matter to people tracking biopharma. The newsletter often distills complex stories — from obesity drug debates to psychedelic promotion concerns — into clear takeaways about winners, losers, and unresolved questions.
She also co-hosts STAT’s weekly biotech podcast, The Readout Loud, where she interviews executives, researchers, and analysts and walks listeners through major developments in the sector. Recent episodes have featured discussions of Eli Lilly’s deal-making strategy, off-the-shelf CAR-T efforts at companies like Allogene, and new hope in treating Huntington’s disease, illustrating her range across oncology, neurology, and platform technologies. Other episodes have tackled longevity investing, biotech’s relationship with China, and leadership changes at key U.S. health agencies, reinforcing her interest in how policy and global dynamics shape biotech’s trajectory.
Across articles, newsletter entries, and podcast segments, Chen’s work is marked by clear, direct explanations of why an advance, setback, or controversy matters for patients, companies, and regulators. For communications teams, she is a reporter whose beat sits at the point where clinical evidence, commercial strategy, and public policy meet, with particular depth on obesity and cardiometabolic drugs within the broader biopharma industry.
4 more health journalists.
Abida Tasnim
Abida Tasnim is a health writer for The Daily Star who focuses on clear, practical guidance that helps readers recognise risks early and act before everyday illnesses turn into wider public health problems. She reports on infectious disease prevention, using measles coverage to show how outbreaks start with individual decisions and behaviours, not just hospital statistics. Her work explains what happens during an outbreak and then anchors the story in simple steps people can take, such as avoiding crowded places when symptoms appear, practising good hygiene, and seeking medical advice early. She writes direct, action‑oriented health explainers that turn clinical questions about contagion and disease burden into everyday choices. Across her beat, she stresses early recognition, timely care, and prevention as the foundations of healthier communities.
Adrián Carballo Casla
Adrián Carballo Casla stands out for turning complex cohort data on ageing into clear, food‑level advice on what older adults should eat to protect brain health and slow chronic disease. He is a researcher in nutritional epidemiology focused on ageing and chronic disease prevention and a postdoctoral researcher in geriatric epidemiology at Karolinska Institutet, writing health explainers for The Conversation. He reports on how diet quality, especially Mediterranean and Mind‑style patterns, shapes dementia risk, grey matter loss and neurocognitive ageing, and how healthy versus pro‑inflammatory diets alter multimorbidity trajectories. His articles translate findings on flavonoids, polyphenols, folate, omega‑3 fats and dietary nitrates into specific food choices and small, practical changes. Much of his coverage is anchored in his own studies on multimorbidity, high‑risk older adults and tailored dietary recommendations, often syndicated to other outlets.
Ahmed Elbediwy
Ahmed Elbediwy brings a lab-based understanding of cancer biology and clinical biochemistry to public-facing health reporting, linking drug mechanisms and molecular pathways to everyday choices about medicines and products. He writes for The Conversation on weight-loss injections, cancer overdiagnosis and anti-ageing supplements, focusing on obesity medicine, cancer signalling, screening trade-offs, skincare and supplement science. His pieces on GLP-1 drugs such as Ozempic, Wegovy and Mounjaro explain why some people do not respond, how gut hormones and appetite signals work, and where psychological support and nutrition fit alongside prescriptions. He co-authors explainers on cancer risk and overdiagnosis and on whether supplements can reverse ageing, separating established knowledge from emerging research. An award-winning senior lecturer at Kingston University, he favours clear, structured explainers, careful definition of key terms and evidence-based appraisal over hype.
Amanda Sheppeard
Amanda Sheppeard is a managing editor and health journalist known for long, detailed explainers that connect complex clinical research, disability policy and political narratives with the daily realities of doctors and patients. She works at The Medical Republic across editorial leadership and commercial content while reporting widely on medicine for its specialist titles. Her real beat spans autism, disability policy, autoimmune disease, infectious threats and system pressures in primary care and hospitals. She covers subjects such as autism diagnosis and the NDIS, rheumatology’s clinical shifts, weight-loss agents in rheumatoid arthritis, infection control, antimicrobial resistance and new modalities like CAR T-cell therapy and microneedles. She reports by doing the synthesis inside the story, linking trial design, molecular targets, funding rules and policy changes to concrete decisions and workflows in clinics and hospitals.